Effect of enterally administered n-3 polyunsaturated fatty acids in acute pancreatitis -: a prospective randomized clinical trial
Effect of enterally administered n-3 polyunsaturated fatty acids in acute pancreatitis -: a prospective randomized clinical trial
复制标题
DOI：
10.1016/j.clnu.2004.12.008
复制
发表时间：
2005-04-01
影响因子：
6.3
通讯作者：
Antal, M
中科院分区：
文献类型：
--
作者：
Lasztity, N;Hamvas, J;Antal, M
背景：在急性胰腺炎 (AP) 中，给予 n-3 多不饱和脂肪酸 (PUFA) 可能通过调节类二十烷酸合成来改变疾病进程。患者和方法：在一项对 28 名中重度 AP 患者进行的前瞻性随机临床试验中，14 名患者肠内接受 n-3 PUFA（鱼油）（3.3 克/天，持续 5-7 天）。在入院时、第 3 天、第 7 天和第 14 天测量红细胞超氧化物歧化酶 (SOD) 活性、血清总抗氧化状态 (TAS)、维生素 A 和 E、脂肪酸、C 反应蛋白、转甲状腺素蛋白浓度。结果：接受 n-3 PUFA 补充的患者血脂中 n-3 与 n-6 LCPUFA 的比率显着增加，而对照组则保持不变。补充剂导致住院时间（13.07 +/- 6.70 vs. 19.28 +/- 7.18 天，P < 0.05）和空肠喂养时间（10.57 +/- 6.70 vs. 17.57 +/- 10.52，P < 0.05）显着缩短。 6/14 (42%) 的治疗患者和 9/14 (64%) 的对照患者出现并发症。补充组第3天SOD活性显着升高（P < 0.05），但其他抗氧化剂和急性期反应物两组间无显着差异。结论：基于缩短空肠喂养时间和住院时间，使用富含 n-3 PUFA 的肠内配方治疗 AP 似乎具有临床益处。 (c) 2005 Elsevier Ltd. 保留所有权利。
Background: In acute pancreatitis (AP) administration of n-3 polyunsaturated fatty acids (PUFAs) might change the course of the disease through modulation of eicosanoid synthesis. Patients and Methods: In a prospective, randomized clinical trial from 28 patients with moderate-severe AP, 14 received n-3 PUFAs (fish oil) enterally (3.3 g/day for 5-7 days). Measurement of erythrocyte superoxide-dysmutase (SOD) activity, serum total antioxidant status (TAS), vitamin A and E, fatty acids, C-reactive protein, transthyretin concentrations were performed at admission, day 3, 7 and 14. Results: The n-3 to n-6 LCPUFA ratios increased significantly in serum lipids of the patients receiving n-3 PUFA supplementation, whereas remained unchanged in the controls. Supplementation resulted in significant decrease in length of hospitalization (13.07 +/- 6.70 vs. 19.28 +/- 7.18 days, P < 0.05) and jejunal feeding (10.57 +/- 6.70 vs. 17.57 +/- 10.52, P < 0.05). Complications developed in 6/14 (42%) of treated and 9/14 (64%) of control patients. The SOD activity was significantly higher at day 3 in the supplemented group (P < 0.05), but there were no significant differences between the two groups in other antioxidants and acute phase reactants. Conclusion: The use of enteral formula enriched with n-3 PUFAs in the treatment of AP seems to have clinical benefits based upon the shortened time of jejunal feeding and hospital stay. (c) 2005 Elsevier Ltd. All rights reserved.